| Document Date: 2015-04-27 07:57:32
Open Document File Size: 25,96 KBShare Result on Facebook
City FLORHAM PARK / London / / Company Shionogi Inc. / Shionogi & Co. Ltd. / Shionogi Ltd. / IMMEDIATE RELEASE SHIONOGI & CO. LTD / / Country United States / United Kingdom / / Event FDA Phase / / IndustryTerm healthcare system / pharmaceutical / foreign healthcare reforms / therapeutic solution / with respect to product / / MedicalCondition chronic non-cancer pain receiving opioid therapy / Opioid Induced Constipation / cancer / chronic non-cancer pain / Opioid Bowel Dysfunction / obesity / opioid-induced constipation / infectious diseases / pain/CNS disorders / metabolic disease / chronic opioid therapy / gastrointestinal disorders / chronic noncancer pain / / Person Juan Camilo Arjona Ferreira / / Position Senior Vice President Clinical Development / / Product TREATMENT OF OPIOID / / PublishedMedium The American Journal / / URL www.shionogi.co.jp / www.shionogi.com / www.shionogi.eu / /
SocialTag |
NOT FOR IMMEDIATE RELEASE SHIONOGI & CO., LTD ANNOUNCES THAT NALDEMEDINE MEETS PRIMARY ENDPOINT IN A PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION FLORHAM PARK, NJ (March 30, 2015) – Naldemedine, an i